Any current/future new fundraising through debt or equity?

The company currently has a low debt-equity ratio of around 2%, primarily due to working capital needs. There are no expectations or plans to take on any further loans in the near future. Working capital is currently locked in GST, expected to be released in the next 3-4 months, which will fund growth. The management does not indicate any plans for fundraising through equity in the near term. Growth is expected to be funded through internal accruals and released working capital rather than new borrowing or equity issuance.

Any current/future capex/capital investment/strategic investment?

Kopran Limited is awaiting environmental clearance for two multiproduct plants at the Panoli facility, which represents a major spare capacity expected to contribute to revenue by next year. The company has completed planned expansions related to the Production Linked Incentive (PLI) scheme despite not receiving PLI approval, implying continued investment in capacity without incentives. New capacities and expansions in API business along with newer, higher-value molecules are key growth drivers. Kopran is focused on developing new products such as Amoxiclav formulations, diabetes-related APIs

Future growth expectations in sales/revenue/volumes?

Kopran expects to double its API business revenues in the next three years due to capacity expansions and higher-value new molecules. Formulation business is projected to grow steadily, with improved margins and diversification into regulated markets like the US, UK, Europe, Latin America, and Southeast Asia. New product filings and approvals (e.g., Amoxiclav, Dapagliflozin, Ticagrelor, Rivaroxaban) are expected to drive growth from 2024 onward, with significant regulated market traction from 2025. Growth rate projections: 10%-15% in the next 1-2 years, increasing to 20%-25% later. Int

Future growth expectations in earnings/operating earnings/profits/EPS?

Kopran expects to double its revenues over the next three years, with FY2023 as the base year. Growth drivers include expansion in API business capacities, launch of newer, higher-value molecules, and filing of DMFs for regulated markets. EBITDA margins are expected to improve and normalize following stabilization of prices and demand, as seen in Q2 FY2024. Formulation business margins are stable, with steady growth expected from new product registrations and entry into new markets. New products like Dapagliflozin, Apixaban, and others are approved and expected to drive future growth, especial

Kopran LtdQ2 FY24Pharmaceuticals & Biotechnology

Kopran Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹271P/E: 53.7Market Cap: ₹1.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Kopran expects to double its API business revenues in the next three years due to capacity expansions and higher-value new molecules.
Formulation business is projected to grow steadily, with improved margins and diversification into regulated markets like the US, UK, Europe, Latin America, and Southeast Asia.
New product filings and approvals (e.g., Amoxiclav, Dapagliflozin, Ticagrelor, Rivaroxaban) are expected to drive growth from 2024 onward, with significant regulated market traction from 2025.
Growth rate projections: 10%-15% in the next 1-2 years, increasing to 20%-25% later.
Integration from API to formulation (vertical integration) is expected to strengthen over 3-4 years, reducing volatility and enhancing margins.
Geographic diversification will gradually reduce dependence on South Africa/Africa, with faster expansion in other regions.
Panoli facility’s environmental clearance and commercial launch expected in the coming year will contribute additional capacity and sales.

Margin guidance

Category 3

Kopran expects to double its revenues over the next three years, with FY2023 as the base year.
Growth drivers include expansion in API business capacities, launch of newer, higher-value molecules, and filing of DMFs for regulated markets.
EBITDA margins are expected to improve and normalize following stabilization of prices and demand, as seen in Q2 FY2024.
Formulation business margins are stable, with steady growth expected from new product registrations and entry into new markets.
New products like Dapagliflozin, Apixaban, and others are approved and expected to drive future growth, especially with regulated market approvals anticipated by 2024-2026.
Integration of APIs to formulations is a slow but strategic process that will provide margin benefits and business stability.
Overall, management assures consistent growth and improved profitability supported by capacity expansions and new product launches.

See what Kopran Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently has a low debt-equity ratio of around 2%, primarily due to working capital needs.
There are no expectations or plans to take on any further loans in the near future.
Working capital is currently locked in GST, expected to be released in the next 3-4 months, which will fund growth.
The management does not indicate any plans for fundraising through equity in the near term.
Growth is expected to be funded through internal accruals and released working capital rather than new borrowing or equity issuance.

Order book

- Kopran Limited did not explicitly mention the current or expected order book or pending orders during the November 22, 2023 conference call excerpt. - The company highlighted ongoing filings of dossiers (over 250 filed in the last two years) with approvals expected within the next one to two years which will trigger new business. - Discussions with regulated market clients are advanced, including for the US, UK, Europe, and China, indicating strong demand pipeline. - Partnerships with large multinational companies are underway, especially for high-value formulations like Amoxiclav, diabetes, and cardiac products. - New capacities, including the Panoli plant (pending environmental clearance), are expected to contribute revenue soon, indirectly suggesting readiness to fulfill anticipated orders. - Exports form a significant share, with clients in regulated and unregulated markets already tied up or showing interest. No direct numeric order book details were disclosed.

See what Kopran Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Kopran Limited is awaiting environmental clearance for two multiproduct plants at the Panoli facility, which represents a major spare capacity expected to contribute to revenue by next year.
The company has completed planned expansions related to the Production Linked Incentive (PLI) scheme despite not receiving PLI approval, implying continued investment in capacity without incentives.
New capacities and expansions in API business along with newer, higher-value molecules are key growth drivers.
Kopran is focused on developing new products such as Amoxiclav formulations, diabetes-related APIs (Dapagliflozin, Empagliflozin), and cardiac products (Ticagrelor, Rivaroxaban, Apixaban) which have bioequivalence studies underway and dossiers to be filed by end of 2024.
No immediate plans for inorganic growth or acquisitions, but may consider long-term opportunities if they arise.

Track Kopran Ltd — get its next earnings analysis in your feed

How does Kopran Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisKopran Ltd

Rev 3Mar 3

See where Kopran Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Kopran Ltd rank in Pharmaceuticals & Biotechnology?

Compare Kopran Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Kopran Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Sun Pharma Advanced Research Company Ltd (Q1 FY21)
. Key investor presentation takeaways from Sun Pharma Advanced Research Company Ltd's Q1 FY21 investor presentation — and how it ranks against sector peers.
Morepen Laboratories Ltd (Q1 FY27)
575.31 Cr (Page 4) . Key investor presentation takeaways from Morepen Laboratories Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key investor presentation takeaways from Morepen Laboratories Ltd's Q1 FY26 investor presentation — and how it ranks against sector peers.
Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Kopran Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Kopran Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Kopran Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season